Viral vectors for gene-directed enzyme prodrug therapy

Current Gene Therapy

Volumn 6, Issue 6, 2006, Pages 647-670

  Schepelmann, Silke ^a   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer; Chemotherapy; GDEPT; Gene therapy; GPAT; Prodrug; Suicide gene therapy; VDEPT

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; BETA GLUCURONIDASE; CARBOXYLESTERASE; CARBOXYPEPTIDASE G2; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOSINE DEAMINASE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; ENZYME; FLUCYTOSINE; GANCICLOVIR; IRINOTECAN; NITROREDUCTASE; PRODRUG; PURINE NUCLEOSIDE PHOSPHORYLASE; THYMIDINE KINASE; TIRAPAZAMINE;

ADENOVIRUS VECTOR; CANCER CELL; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG POTENCY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE TARGETING; GENETIC ENGINEERING; GLIOMA; HUMAN; LENTIVIRUS VECTOR; LIVER CARCINOMA; MALIGNANT MESOTHELIOMA; MELANOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARVOVIRUS VECTOR; PROTEIN EXPRESSION; RETINOBLASTOMA; RETROVIRUS VECTOR; REVIEW; UNSPECIFIED SIDE EFFECT; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS VECTOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYMES; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; PRODRUGS; VIRUSES;

EID: 33845409424     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652306779010679     Document Type: Review

References (268)

1. Agard, C., Ligeza, C., Dupas, B., Izembart, A., El Kouri, C., Moullier, P. and Ferry, N. (2001) Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis. Cancer Gene Ther., 8: 128-136.
2. Aghi, M., Chou, T.C., Suling, K., Breakefield, X.O. and Chiocca, E.A. (1999) Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res., 59: 3861-3865.
3. Alemany, R., Balague, C. and Curiel, D.T. (2000) Replicative adenoviruses for cancer therapy. Nat. Biotechnol., 18: 723-727.
4. Ali, S., King, G.D., Curtin, J.F., Candolfi, M., Xiong, W., Liu, C., Puntel, M., Cheng, Q., Prieto, J., Ribas, A., Kupiec-Weglinski, J., van Rooijen, N., Lassmann, H., Lowenstein, P. R. and Castro, M. G. (2005) Combined immunostimulation and conditional cytotoxic: gene therapy provide long-term survival in a large glioma model. Cancer Res., 65: 7194-7204.
5. Anders, M., Christian, C., McMahon, M., McCormick, F. and Korn, W.M. (2003) Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res., 63: 2088-2095.
6. Balachandran, S., Roberts, P.C., Kipperman, T., Bhalla, K.N., Compans, R.W., Archer, D.R. and Barber, G.N. (2000) Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/ Caspase-8 death signaling pathway. J. Virol., 74: 1513-1523.
7. Barba, D., Hardin, J., Ray, J. and Gage, F.H. (1993) Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg, 79: 729-735.
8. Barba, D., Hardin, J., Sadelain, M. and Gage, F.H. (1994) Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA, 91: 4348-4352.
9. Barton, K.N., Paielli, D., Zhang, Y., Koul, S., Brown, S.L., Lu, M., Seely, J., Kim, J.H. and Freytag, S.O. (2006) Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol. Ther., 13: 347-356.
10. Barton, K.N., Xia, X., Yan, H., Stricker, H., Heisey, G., Yin, F.F., Nagaraja, T.N., Zhu, G., Kolozsvary, A., Fenstermacher, J.D., Lu, M., Kim, J. H., Freytag, S. O. and Brown, S. L. (2004) A quantitative method for measuring gene expression magnitude and volume delivered by gene therapy vectors. Mol. Ther., 9: 625-631.
11. Barzon, L., Bonaguro, R., Castagliuolo, I., Chilosi, M., Gnatta, E., Parolin, C., Boscaro, M. and Palu, G. (2002) Transcriptionally targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer. J. Clin. Endocrinol. Metab., 87: 5304-5311.
12. Bergelson, J.M., Cunningham, J.A., Droguett, G., Kurt-Jones, E.A., Krithivas, A., Hong, J.S., Horwitz, M.S., Crowell, R.L. and Finberg, R:W. (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science, 275: 1320-1323.
13. Bernt, K.M., Steinwaerder, D.S., Ni, S., Li, Z.Y., Roffler, S.R. and Lieber, A. (2002) Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors. Cancer Res., 62: 6089-6098.
14. Bharara, S., Sorscher, E.J., Gillespie, G.Y., Lindsey, J.R., Hong, J.S., Curlee, K.V., Allan, P.W., Gadi, V.K., Alexander, S.A., Secrist, J.A., 3rd, Parker, W. B. and Waud, W. R. (2005) Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy. Hum. Gene Ther., 16: 339-347.
15. Bian, H., Fournier, P., Moormann, R., Pecters, B. and Schirrmacher, V. (2005) Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein. Int. J. Oncol., 26: 431-439.
16. Bilsland, A.E. anderson, C.J., Fletcher-Monaghan, A.J., McGregor, F., Evans, T.R., Ganly, I., Knox, R.J., Plumb, J.A. and Keith, W.N. (2003) Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene, 22: 370-380.
17. Bischoff, J.R., Kirn, D.H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J.A., Sampson-Johannes, A., Fattaey, A. and McCormick, F. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science, 274: 373-376.
18. Black, M.E., Kokoris, M.S. and Sabo, P. (2001) Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res., 61: 3022-3026.
19. Black, M.E., Newcomb, T.G., Wilson, H.M. and Loeb, L.A. (1996) Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc. Natl. Acad. Sci. USA, 93: 3525-3529.
20. Boviatsis, E.J., Park, J.S., Sena-Esteves, M., Kramm, C.M., Chase, M., Efird, J.T., Wei, MX, Breakefield, X.O. and Chiocca, E.A. (1994) Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res., 54: 5745-5751.
21. Braybrooke, J.P., Slade, A., Deplanque, G., Harrop, R., Madhusudan, S., Forster, M.D., Gibson, R., Makris, A., Talbot, D.C., Steiner, J., White, L., Kan, O., Naylor, S., Carroll, M. W., Kingsman, S. M. and Harris, A. L. (2005) Phase I study of MctXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin. Cancer Res., 11: 1512-1520.
22. Bridgewater, J.A., Springer, C.J., Knox, R.J., Minton, N.P., Michael, N.P. and Collins, M.K. (1995) Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer, 31A: 2362-2370.
23. Brunori, M., Malerba, M., Kashiwazaki, H. and Iggo, R. (2001) Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J. Virol., 75: 2857-2865.
24. Carrio, M., Visa, J., Cascante, A., Estivill, X. and Fillat, C. (2002) Intratumoral activation of cyclophosphamide by retroviral transfer of the cytochrome P450 2B1 in a pancreatic tumor model. Combination with the HSVtk/GCV system. J. Gene Med, 4: 141-149.
25. Castro, M.G., Cowen, R., Williamson, I.K., David, A., Jimenez-Dalmaroni, M.J., Yuan, X., Bigliari, A., Williams, J.C., Hu, J. and Lowenstein, P.R. (2003) Current and future strategies for the treatment of malignant brain tumors. Pharmacol. Ther., 98: 71-108.
26. Chambers, R., Gillespie, G.Y., Soroceanu, L. andreansky, S., Chatterjee, S., Chou, J., Roizman, B. and Whitley, R.J. (1995) Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA, 92:1411-1415.
27. Chang, E., Chalikonda, S., Friedl, J., Xu, H., Phan, G.Q., Marincola, F.M., Alexander, H.R. and Bartlett, D.L. (2005) Targeting vaccinia to solid tumors with local hyperthermia. Hum. Gene Ther., 16: 43 5-444.
28. Chase, M., Chung, R.Y. and Chiocca, E.A. (1998) An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol., 16: 444-448.
29. Check, E. (2003) Harmful potential of viral vectors fuels doubts over gene therapy. Nature, 423: 573-574.
30. Chen, M.J., Green, N.K., Reynolds, G.M., Flavell, JR., Mautner, V., Kerr, D.J., Young, L.S. and Searle, P.F. (2004) Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Ther., 11: 1126-1136.
31. Chevez-Barrios, P., Chintagumpala, M., Mieler, W., Paysse, E., Boniuk, M., Kozinetz, C., Hurwitz, M.Y. and Hurwitz, R.L. (2005) Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin. Oncol., 23: 7927-7935.
32. Choi, V.W., McCarty, D.M. and Samulski, R.J. (2000) AAV hybrid serotypes: improved vectors for gene delivery. Curr. Gene Ther., 5: 299-310.
33. Chung-Faye, G.A., Chen, M.J., Green, N.K., Burton, A. anderson, D., Mautner, V., Searle, P.F. and Kerr, D.J. (2001) In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther., 8: 1547-1554.
34. Cirone, P., Potter, M., Hirte, H. and Chang, P. (2006) Immuno-isolation in cancer gene therapy, Curr. Gene Ther., 6: 181-191.
35. Cowen, R.L., Patterson, A.V., Telfer, B.A., Airley, R.E., Hobbs, S., Phillips, R.M., Jaffar, M., Stratford, I.J. and Williams, K.J. (2003) Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts. Mol. Cancer Ther., 2: 901-909.
36. Cowen, R.L., Williams, J.C., Emery, S., Blakey, D., Darling, J.L., Lowenstein, P.R. and Castro, M.G. (2002) Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane. Cancer Gene Ther., 9: 897-907.
37. Cowen, R.L., Williams, K.J., Chinje, E.C., Jaffar, M., Sheppard, F.C., Telfer, B.A., Wind, N.S. and Stratford, I.J. (2004) Hypoxia targeted gene therapy to increase the efficacy of firapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res., 64: 1396-1402.
38. Crystal, R.G., Hirschowitz, E., Lieberman, M., Daly, J., Kazam, E., Henschke, C., Yankelevitz, D., Kemeny, N., Silverstein, R., Ohwada, A., Russi, T., Mastrangeli, A., Sanders, A., Cooke, J. and Harvey, B. G. (1997) Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum. Gene Ther., 8: 985-1001.
39. Csatary, L.K., Gosztonyi, G., Szeberenyi, J., Fabian, Z., Liszka, V., Bodey, B. and Csatary, C.M. (2004) MTH-68/H oncolytic viral treatment in human high-grade gliomas. J. Neurooncol., 67: 83-93.
40. Culver, K.W., Ram. Z., Wallbridge, S., Ishii, H., Oldfield, E.H. and Blaese, R.M. (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science, 256: 1550-1552.
41. Dalba, C., Klatzmann, D., Logg, C.R. and Kasahara, N. (2005) Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr. Gene Ther., 5: 655-667.
42. Danthinne, X. and Imperiale, M.J. (2000) Production of first generation adenovirus vectors: a review. Gene Ther., 7: 1707-1714.
43. De Palma, M., Venneri, M.A. and Naldini, L. (2003) In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum. Gene Ther., 14: 1193-1206.
44. Dingli, D., Peng, K.W., Harvey, M.E., Greipp, P.R., O'Connor, M.K., Cattanco, R., Morris, J.C. and Russell, S.J. (2004) Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood, 103: 1641-1646.
45. Djeha, H.A., Todryk, S.M., Pelech, S., Wrighton, C.J., Irvine, A.S., Mountain, A. and Lipinski, K.S. (2005) Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase/CB1954 is enhanced by high-level coexpression of heat shock protein 70. Cancer Gene Ther., 12: 560-571.
46. Doronin, K., Kuppuswamy, M., Toth, K., Tollefson, A.E., Krajcsi, P., Krougliak, V. and Wold, W.S. (2001) Tissue-specific, turnor-selective, replication-competent adenovirus vector for Cancer Gene Therapy. J Virol., 75: 3314-3324.
47. Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A.E. and Wold, W.S. (2000) Turnor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol., 74: 6147-6155.
48. Eaton, J.D., Perry, M.J., Todryk, S.M., Mazucco, R.A., Kirby, R.S., Griffiths, J.R. and Dalgleish, A.G. (2001) Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques. Gene Ther., 8: 557-567.
49. Edelstein, M.L., Abedi, M.R., Wixon, J. and Edelstein, R.M. (2004) Gene therapy clinical trials worldwide 1989-2004-an overview. J. Gene Med, 6: 597-602.
50. Engel-Herbert, I., Wertier, O., Teifke, J.P., Mebatsion, T., Mettenleiter, T.C. and Romer-Oberdorfer, A. (2003) Characterization of a recombinant Newcastle disease virus expressing the green fluorescent protein. J. Virol. Methods, 108: 19-28.
51. Ezzeddine, Z.D., Martuza, R.L., Platika, D., Short, M.P., Malick, A., Choi, B. and Breakefield, X.O. (1991) Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol.; 3: 608-614.
52. Feng, M., Jackson, W.H., Jr., Goldman, C.K., Rancourt, C., Wang, M., Dusing, S.K., Siegal, G. and Curiel, D.T. (1997) Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat. Biotechnol., 15: 866-870.
53. Fenner, F. (1996). Poxviruses. In: Fields Virology, Third edition, Fields, Lippincott-Raven Publishers, Philadelphia, pp. 2673-2702.
54. Fernandez, M., Porosnicu, M., Markovic, D. and Barber, G.N. (2002) Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol., 76: 895-904.
55. Ferrari, F.K., Samulski, T., Shenk, T. and Samulski, R.J. (1996) Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol., 70: 3227-3234.
56. Fisher, K.J., Jooss, K., Alston, J., Yang, Y., Haecker, S.E., High, K., Pathak, R., Raper, S.E. and Wilson, J.M. (1997) Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med., 3: 306-312.
57. Follenzi, A. and Gupta, S. (2004) The promise of lentiviral gene therapy for liver cancer. J. Hepatol., 40: 337-340.
58. Follenzi, A. and Naldini, L. (2002) Generation of HIV-1 derived lentiviral vectors. Methods. Enzymol, 346: 454-465.
59. Fong Y, K.N., Jamagin W, Stanziale S, Guilfoyle B, Gusani N, Joe J, Blumgart L, Lakeman F, Gammon K, Perterkin J, Horsburgh B, Tufaro F (2002). Phase 1 study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases. Paper presented at: Am Soc Clin Oncol Ann Meeting (Orlando, USA).
60. Francis, R.J., Sharma, S.K., Springer, C., Green, A.J., Hope-Stone, L.D., Sena, L., Martin, J., Adamson, K.L., Robbins, A., Gumbrell, L., O'Malley, D., Tsiompanou, E., Shahbakhti, H., Webley, S., Hochhauser, D., Hilson, A. J., Blakey, D. and Begent, R. H. (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br. J. Cancer, 87: 600-607.
61. Freytag, S.O., Khil, M., Stricker, H., Peabody, J., Menon, M., DePeralta-Venturina, M., Nafziger, D., Pegg, J., Paielli, D., Brown, S., Barton, K., Lu, M., Aguilar-Cordova, E. and Kim, J. H. (2002) Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res., 62: 4968-4976.
62. Freytag, S.O., Rogulski, K.R., Paielli, D.L., Gilbert, J.D. and Kim, J.H. (1998) A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther., 9: 1323-1333.
63. Freytag, S.O., Stricker, H., Pegg, J., Paielli, D., Pradhan, D.G., Peabody, J., DePeralta-Venturina, M., Xia, X., Brown, S., Lu, M. and Kim, J.H. (2003) Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res., 63: 7497-7506.
64. Fu, X., Tao, L., Jin, A., Vile, R., Brenner, M.K. and Zhang, X. (2003) Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol. Ther., 7: 748-754.
65. Fuerer, C. and Iggo, R. (2002) Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther., 9: 270-281.
66. Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P.S., McDonnell, T.J., Mitlianga, P., Shi, Y.X., Levin, V.A., Yung, W.K. and Kyritsis, A.P. (2000) A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene, 19: 2-12.
67. Galanis, E., Bateman, A., Johnson, K., Diaz, R.M., James, C.D., Vile, R. and Russell, S.J. (2001) Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum. Gene Ther., 12: 811-821.
68. Ganly, I., Kim, D., Eckhardt, G., Rodriguez, G.I., Soutar, D.S., Otto, R., Robertson, A.G., Park, O., Gulley, M.L., Heise, C., Von Hoff, D. D., Kaye, S. B. and Eckhardt, S. G. (2000) A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res., 6: 798-806.
69. Gao, G., Vandenberghe, L.H. and Wilson, J.M. (2005) New Recombinant Scrotypes of AAV Vectors. Curr. Gene Ther., 5: 285-297.
70. Gerolami, R., Cardoso, J., Lewin, M., Bralet, M.P., Sa Cunha, A., Clement, O., Brechot, C. and Tran, P.L. (2000) Evaluation of HSV-tk gene therapy in a rat model of chemically induced hepatocellular carcinoma by intratumoral and intrahepatic artery routes. Cancer Res., 60: 993-1001.
71. Gerolami, R., Uch, R., Faivre, J., Garcia, S., Hardwigsen, J., Cardoso, J., Mathieu, S., Bagnis, C., Brechot, C. and Mannoni, P. (2004) Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors. J. Hepatol, 40: 291-297.
72. Gnant, M.F., Puhlmann, M., Alexander, H.R., Jr. and Bartlett, D.L. (1999) Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res., 59: 3396-3403.
73. Greco, O. and Dachs, G.U. (2001) Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J. Cell. Physiol, 187: 22-36.
74. Grimm, D. and Kay, M.A. (2003) From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther., 3: 281-304.
75. Groot-Wassink, T., Aboagye, E.O., Wang, Y., Lemoine, N.R., Keith, W.N. and Vassaux, G. (2004) Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res., 64: 4906-4911.
76. Haack, K., Linnebacher, M., Eisold, S., Zoller, M., von Knebel Doeberitz, M. and Gebert, J. (2000) Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Ther., 7: 1357-1364.
77. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J. I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L. E., Wissler, M., Prinz, C., Rabbitts, T. H., Le Deist, F. and Fischer, A., Cavazzana-Calvo, M. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302: 415-419.
78. Hamstra, D.A., Rice, D.J., Fahmy, S., Ross, B.D. and Rehemtulla, A. (1999) Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum. Gene Ther., 10: 1993-2003.
79. Hasenburg, A., Tong, X.W., Fischer, D.C., Rojas-Martinez, A., Nyberg-Hoffman, C., Kaplan, A.L., Kaufman, R.H., Ramzy, I., Aguilar-Cordova, E. and Kieback, D.G. (2001) Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol. Oncol, 83: 549-554.
80. Hecht, J.R., Bedford, R., Abbruzzese, J.L., Lahoti, S., Reid, T.R., Soetikno, R.M., Kim, D.H. and Freeman, S.M. (2003) A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res., 9: 555-561.
81. Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L. and Kim, D. (2000) An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med, 6: 1134-1139.
82. Hermiston, T.W. and Kuhn, I. (2002) Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther., 9: 1022-1035.
83. High, K.A. (2004) Clinical gene transfer studies for hemophilia B. Semin. Thromb. Hemost, 30: 257-267.
84. Huber, B.E., Richards, C.A. and Krenitsky, T.A. (1991) Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA, 88: 8039-8043.
85. Humphreys, M.J., Ghaneh, P., Greenhalf, W., Campbell, F., Clayton, T.M., Everett, P., Huber, B.E., Richards, C.A., Ford, M.J. and Neoptolemos, J.P. (2001) Hepatic intra-arterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases. Gene Ther., 8: 1241-1247.
86. Hwang, K.S., Cho, W.K., Yoo, J., Yun, H.J., Kim, S. and Im, D.S. (2005) Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. BMC. Cancer, 5: 51.
87. Ichikawa, T. and Chiocca, E.A. (2001) Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res., 61: 5336-5339.
88. Immonen, A., Vapalahti, M., Tyynela, K., Hurskainen, H., Sandmair, A., Vanninen, R., Langford, G., Murray, N. and Yla-Herttuala, S. (2004) AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther., 10: 967-972.
89. Irving, J., Wang, Z., Powell, S., O'Sullivan, C., Mok, M., Murphy, B., Cardoza, L., Lebkowski, J.S. and Majumdar, A.S. (2004) Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther., 11: 174-185.
90. Ishii-Morita, H., Agbaria, R., Mullen, C.A., Hirano, H., Koeplin, D.A., Ram, Z., Oldfield, E.H., Johns, D.G. and Blaese, R.M. (1997) Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther., 4: 244-251.
91. Jakubczak, J.L., Ryan, P., Gorziglia, M., Clarke, L., Hawkins, L.K., Hay, C., Huang, Y., Kaloss, M., Marinov, A., Phipps, S., Pinkstaff, A., Shirley, P., Skripchenko, Y., Stewart, D., Forry-Schaudies, S. and Hallenbeck, P. L. (2003) An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res., 63: 1490-1499.
92. Janouskova, O., Sima, P. and Kunke, D. (2003) Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cell: decrease of oncogenicity and induction of protection. Int. J. Oncol., 22: 569-577.
93. Johnson, L., Shen, A., Boyle, L., Kunich, J., Pandey, K., Lemmon, M., Hermiston, T., Giedlin, M., McCormick, F. and Fattaey, A. (2002) Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell, 1: 325-337.
94. Jounaidi, Y., Chen, C.S., Veal, G.J. and Waxman, D.J. (2006) Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol. Cancer Ther., 5: 541-555.
95. Jounaidi, Y. and Waxman, D.J. (2001) Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy. Cancer Res., 61: 4437-4444.
96. Jounaidi, Y. and Waxman, D.J. (2004) Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy.Cancer Res., 64: 292-303.
97. Kan, O., Griffiths, L., Baban, D., Iqball, S., Uden, M., Spearman, H., Slingsby, J., Price, T., Esapa, M., Kingsman, S., Kingsman, A., Slade, A. and Naylor, S. (2001) Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther., 8: 473-482.
98. Kanazawa, T., Mizukami, H., Okada, T., Hanazono, Y., Kume, A., Nishino, H., Takeuchi, K., Kitamura, K., Ichimura, K. and Ozawa, K. (2003) Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther., 10: 51-58.
99. Kaneko, S., Hallenbeck, P., Kotani, T., Nakabayashi, H., McGarrity, G., Tamaoki, T. anderson, W.F. and Chiang, Y.L. (1995) Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res., 55: 5283-5287.
100. Kaplitt, M.G., Leone, P., Samulski, R.J., Xiao, X., Pfaff, D.W., O'Malley, K.L. and During, M.J. (1994) Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet., 8: 148-154.
101. Kay, M.A., Manno, C.S., Ragni, M.V., Larson, P.J., Couto, L.B., McClelland, A., Glader, B., Chew, A.J., Tai, S.J., Herzog, R.W., Arruda, V., Johnson, F., Scallan, C., Skarsgard, E., Flake, A. W. and High, K. A. (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet., 24: 257-261.
102. Kay, M.A. and Nakai, H. (2003) Looking into the safety of AAV vectors. Nature, 424: 251.
103. Khuri, F.R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I.F., Romel, L., Gore, M.,Ironside, J., MacDougall, R.H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K. and Kim, D. H. (2000) a controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 6: 879-885.
104. Kievit, E., Bershad, E., Ng, E., Sethna, P., Dev, I., Lawrence, T.S. and Rehemtulla, A. (1999) Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res., 59: 1417-1421.
105. Kimura, O., Yamaguchi, Y., Gunning, K.B., Teeter, L.D., Husain, F. and Kuo, M.T. (1994) Retroviral delivery of DNA into the livers of transgenic mice bearing premalignant and malignant hepatocellular carcinomas. Hum. Gene Ther., 5: 845-852.
106. King, G.D., Curtin, J.F., Candolfi, M., Kroeger, K., Lowenstein, P.R. and Castro, M.G. (2005) Gene therapy and targeted toxins for glioma. Curr. Gene Ther., 5: 535-57.
107. Kirn, D., Martuza, R.L. and Zwiebel, J. (2001) Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med., 7: 781-787.
108. Kirn, D., Niculescu-Duvaz, I., Hallden, G. and Springer, C.J. (2002) The emerging fields of suicide gene therapy and virotherapy. Trends Mol. Med., 8: S68-73.
109. Kirn, D.H. and McCormick, F. (1996) Replicating viruses as selective cancer therapeutics. Mol. Med. Today, 2: 519-527.
110. Klatzmann, D., Valery, C.A., Bensimon, G., Marro, B., Boyer, O., Mokhtari, K., Diquet, B., Salzmann, J.L. and Philippon, J. (1998) A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastorna. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther., 9: 2595-2604.
111. Knox, R.J., Friedlos, F., Marchbank, T. and Roberts, J.J. (1991) Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem. Pharmacol., 42: 1691-1697.
112. Koeneman, K.S., Kao, C., Ko, S.C., Yang, L., Wada, Y., Kallmes, D.F., Gillenwater, J.Y., Zhau, H.E., Chung, L.W. and Gardner, T.A. (2000) Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J. Urol., 18: 102-110.
113. Konnikova, L., Simeone, M.C., Kruger, M.M., Kotecki, M. and Cochran, B.H. (2005) Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res., 65: 6516-6520.
114. Kubo, H., Gardner, T.A., Wada, Y., Koeneman, K.S., Gotoh, A., Yang, L., Kao, C., Lim, S.D., Amin, M.B., Yang, H., Black, M. E., Matsubara, S., Nakagawa, M., Gillenwater, J. Y., Zhau, H. E. and Chung, L. W. (2003) Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum. Gene Ther., 14: 227-241.
115. Kurihara, T., Brough, D.E., Kovesdi, I. and Kufe, D.W. (2000) Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest, 106: 763-771.
116. Kwak, H., Horig, H. and Kaufman, H.L. (2003) Poxviruses as vectors for cancer immunotherapy. Curr. Opin. Drug Discov. Devel., 6: 161-168.
117. Lambright, E.S., Amin, K., Wiewrodt, R., Force, S.D., Lanuti, M., Propert, K.J., Litzky, L., Kaiser, L.R. and Albelda, S.M. (2001) Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther., 8: 946-953.
118. Lan, K.H., Kanai, F., Shiratori, Y., Ohashi, M., Tanaka, T., Okudaira, T., Yoshida, Y., Hamada, H. and Omata, M. (1997) In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res., 57: 4279-4284.
119. Lanuti, M., Gao, G.P., Force, S.D., Chang, M.Y., El Kouri, C., Amin, K.M., Hughes, J.V., Wilson, J.M., Kaiser, L.R. and Albelda, S.M. (1999) Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum. Gene Ther., 10: 463-475.
120. Latchman, D.S. (2002) Herpes simplex virus vectors for gene delivery to a variety of different cell types. Curr. Gene Ther., 2: 415-426.
121. Lee, H., Song, J.J., Kim, E., Yun, C.O., Choi, J., Lee, B., Kim, J., Chang, J.W. and Kim, J.H. (2001) Efficient gene transfer of VSV-G pseudotyped retroviral vector to human brain tumor. Gene Ther., 8: 268-273.
122. Levine, B., Huang, Q., Isaacs, J.T., Reed, J.C., Griffin, D.E. and Hardwick, J.M. (1993) Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature, 361: 739-742.
123. Lewis, P., Hensel, M. and Emerman, M. (1992) Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J., 11: 3053-3058.
124. Lewis, P.F. and Emerman, M. (1994) Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol, 68: 510-516.
125. Liebman, J.M., Burbelo, P.D., Yamada, Y., Fridman, R. and Kleinman, H.K. (1993) Altered expression of basement-membrane components and collagenases in ascitic xenografts of OVCAR-3 ovarian cancer cells. Int. J. Cancer, 55: 102-109.
126. Lipinski, K.S., Djeha, A.H., Ismail, T., Mountain, A., Young, L.S. and Wrighton, C.J. (2001) High-level, beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. Mol. Ther., 4: 365-371.
127. Lipinski, K.S., Pelech, S., Mountain, A., Irvine, A.S., Kraaij, R., Bangma, C.H., Mills, K.H. and Todryk, S.M. (2006) Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity. Cancer Immunol. Immuno. Ther., 55: 347-354.
128. Liu, B.L., Robinson, M., Han, Z.Q., Branston, R.H., English, C., Reay, P., McGrath, Y., Thomas, S.K., Thornton, M., Bullock, P., Love, C. A. and Coffin, R. S. (2003) ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther., 10: 292-303.
129. Liu, Y. and Deisseroth, A. (2006) Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy. Cancer Gene Ther.
130. Liu, Y., Ye, T., Maynard, J., Akbulut, H. and Deisseroth, A. (2006) Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy. Cancer Gene Ther., 13: 346-356.
131. Logg, C.R., Logg, A., Matusik, R.J., Bochner, B.H. and Kasahara, N. (2002) Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J. Virol., 76: 12783-12791.
132. Logg, C.R., Logg, A., Tai, C.K., Cannon, P.M. and Kasahara, N. (2001a) Genomic stability of murine leukemia viruses containing insertions at the Env-3′ untranslated region boundary. J. Virol., 75: 6989-6998.
133. Logg, C.R., Tai, C.K., Logg, A. anderson, W.F. and Kasahara, N. (2001b) A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum. Gene Ther., 12: 921-932.
134. Long, Z., Li, L.P., Grooms, T., Lockey, C., Nader, K., Mychkovsky, I., Mueller, S., Burimski, I., Ryan, P., Kikuchi, G., Ennist, D., Marcus, S., Otto, E., McGarrity, G. (1998) Biosafety monitoring of patients receiving intracerebral injections of routine retroviral vector producer cells. Hum. Gene Ther., 9: 1165-1172.
135. Lukashev, A.N., Fuerer, C., Chen, M.J., Searle, P. and Iggo, R. (2005) Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954. Hum. Gene Ther., 16: 1473-1483.
136. Maione, D., Della Rocca, C., Giannetti, P., D'Arrigo, R., Liberatoscioli, L., Franlin, L. L., Sandig, V., Ciliberto, G., La Monica, N. and Savino, R. (2001) An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes pre-existing immunity to adenovirus. Proc. Natl. Acad. Sci. USA, 98: 598-691.
137. Mandel, R.J. and Burger, C. (2004) Clinical trials in neurological disorders using AAV vectors: promises and challenges. Curr. Opin. Mol. Ther., 6: 482-490.
138. Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Zehnder, J., Rustagi, P. K., Nakai, H., Chew, A., Leonard, D., Wright, J. F., Lessard, R. R., Sommer, J. M., Tigges, M., Sabatino, D., Luk, A., Jiang, H., Mingozzi, F., Couto, L., Ertl, H. C., High, K. A. and Kay, M. A. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med, 12: 342-347.
139. Manome, Y., Wen, P.Y., Chen, L., Tanaka, T., Dong, Y., Yamazoe, M., Hirshowitz, A., Kufe, D.W. and Fine, H.A. (1996) Gene therapy for malignant gliomas using replication incompetent retroviral and adeno-viral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther., 3: 513-520.
140. Marais, R., Spooner, R.A., Light, Y., Martin, J. and Springer, C.J. (1996) Gene-directed enzyme prodrug therapy with a mustard prodrug/ carboxypeptidase G2 combination. Cancer Res., 56: 4735-4742.
141. Marais, R., Spooner, R.A., Stribbling, S.M., Light, Y., Martin, J. and Springer, C.J. (1997) A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat. Biotechnol., 15: 1373-1377.
142. Markert, J.M., Medlock, M.D., Rabkin, S.D., Gillespie, G.Y., Todo, T., Hunter, W.D., Palmer, C.A., Feigenbaum, F., Tornatore, C., Tufaro, F. and Martuza, R.L. (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther., 7: 867-874.
143. Martignone, S., Menard, S., Bufalino, R., Cascinelli, N., Pellegrini, R., Tagliabue, E. andreola, S., Rilke, F. and Colnaghi, M.I. (1993) Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. J Natl. Cancer Inst., 85: 398-402.
144. Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L. and Coen, D.M. (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 252: 854-856.
145. Mavria, G., Harrington, K.J., Marshall, C.J. and Porter, C.D. (2005) In vivo efficacy of HSV-TK transcriptionally targeted to the tumour vasculature is augmented by combination with cytotoxic chemotherapy. J. Gene Med., 7: 263-275.
146. McCart, J.A., Puhlmann, M., Lee, J., Hu, Y., Libutti, S.K., Alexander, H.R. and Bartlett, D.L. (2000) Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther., 7: 1217-1223.
147. McCart, J.A., Ward, J.M., Lee, J., Hu, Y., Alexander, H.R., Libutti, S.K., Moss, B. and Bartlett, D.L. (2001) Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res., 61: 8751-8757.
148. McCormick, F. (2003) Cancer-specific viruses and the development of ONYX-015. Cancer Biol. Ther., 2: S157-160.
149. McKee, T.D., Grandi, P., Mok, W., Alexandrakis, G., Insin, N., Zimmer, J.P., Bawendi, M.G., Boucher, Y., Breakefield, X.O. and Jain, R.K. (2006) Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res., 66: 2509-2513.
150. Menei, P., Boisdron-Celle, M., Croue, A., Guy, G. and Benoit, J.P. (1996) Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery, 39: 117-123.
151. Miyatake, S., Martuza, R.L. and Rabkin, S.D. (1997) Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther., 4: 222-228.
152. Mineta, T., Rabkin, S.D., Yazaki, T., Hunter, W.D. and Martuza, R.L. (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1: 938-943.
153. Miyoshi, H., Blomer, U., Takahashi, M., Gage, F.H. and Verma, I.M. (1998) Development of a self-inactivating lentivirus vector. J. Virol., 72: 8150-8157.
154. Moolten, F.L. (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46: 5276-5281.
155. Moriuchi, S., Wolfe, D., Tamura, M., Yoshimine, T., Miura, F., Cohen, J.B. and Glorioso, J.C. (2002) Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther., 9584-91.
156. Moriuchi, S., Glorioso, J.C., Martino, M., Izumoto, S., Wolfe, D., Huang, S., Cohen, J.B. and Yoshimine, T. (2005) Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase. Cancer Gene Ther., 12: 487-96.
157. Morris, J.C., Ramsey, W.J., Wildner, O., Muslow, H.A., Aguilar-Cordova, E. and Blaese, R.M. (2000) A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganci-clovir in patients with cutaneous metastatic malignant melanoma. Hum. Gene Ther., 11: 487-503.
158. Morris, J.C. and Wildner, O. (2000) Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol. Ther., 1: 56-62.
159. Moss, R.B., Rodman, D., Spencer, L.T., Aitken, M.L., Zeitlin, P.L., Waltz, D., Milla, C., Brody, A.S., Clancy, J.P., Ramsey, B., Hamblett, N. and Heald, A. E. (2004) Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest, 125: 509-521.
160. Mukherjee, S., Haenel, T., Himbeck, R., Scott, B., Ramshaw, I., Lake, R.A., Harnett, G., Phillips, P., Morey, S., Smith, D., Davidson, J. A., Musk, A. W. and Robinson, B. (2000) Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther., 7: 663-670.
161. Muzyczka, N. (1992) Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol., 158: 97-129.
162. Nakamura, H., Mullen, J.T., Chandrasekhar, S., Pawlik, T.M., Yoon, S.S. and Tanabe, K.K. (2001) Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res., 61: 5447-5452.
163. Nakamura, T., Peng, K.W., Harvey, M., Greiner, S., Lorimer, I.A., James, C.D. and Russell, S.J. (2005) Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol., 23: 209-214.
164. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F.H., Verma, I.M. and Trono, D. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 272: 263-267.
165. Nanda, D., Vogels, R., Havenga, M., Avezaat, C.J., Bout, A. and Smitt, P.S. (2001) Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res., 61: 8743-8750.
166. Napier, M.P., Sharma, S.K., Springer, C.J., Bagshawe, K.D., Green, A.J., Martin, J., Stribbling, S.M., Cushen, N., O'Malley, D. and Begent, R.H. (2000) Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin. Cancer Res., 6: 765-772.
167. Nemunaitis, J., Cunningham, C., Tong, A.W., Post, L., Netto, G., Paulson, A.S., Rich, D., Blackburn, A., Sands, B., Gibson, B., Randlev, B. and Freeman, S. (2003) Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther., 10: 341-352.
168. Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., McCarty, T., Landers, S., Maples, P., Romel, L., Randlev, B., Reid, T., Kaye, S. and Kirn, D. (2000) Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res., 60: 6359-6366.
169. Niculescu-Duvaz, I., Spooner, R., Marais, R. and Springer, C.J. (1998) Gene-directed enzyme prodrug therapy. Bioconjug. Chem., 9: 4-22.
170. Niculescu-Duvaz, I. and Springer, C.J. (2004) Introduction to the back-ground, principles, and state of the art in suicide gene therapy. Methods Mol. Med, 90: 1-28.
171. Norman, K.L. and Lee, P.W. (2005) Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov. Today, 10: 847-855.
172. Okabe, S., Arai, T., Yamashita, H. and Sugihara, K. (2003) Adenovirus-mediated prodrug-enzyme therapy for CEA-producing colorectal cancer cells. J. Cancer Res. Clin. Oncol., 129: 367-373.
173. Okada, H., Miyamura, K., Itoh, T., Hagiwara, M., Wakabayashi, T., Mizuno, M., Colosi, P., Kurtzman, G. and Yoshida, J. (1996) Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene Ther., 3: 957-964.
174. Okada, T., Caplen, N.J., Ramsey, W.J., Onodera, M., Shimazaki, K., Nomoto, T., Ajalli, R., Wildner, O., Morris, J., Kume, A., Hamada, H., Blaese, R. M. and Ozawa, K. (2004) In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo. J. Gene Med, 6: 288-299.
175. Okegawa, T., Pong, R.C., Li, Y., Bergelson, J.M., Sagalowsky, A.I. and Hsieh, J.T. (2001) The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res., 61: 6592-6600.
176. Oosterhoff, D., Witlox, M.A., van Beusechem, V.W., Haisma, H.J., Schaap, G.R., Bras, J., Kruyt, F.A., Molenaar, B., Boven, E., Wuisman, P.I., Pinedo, H. M. and Gerritsen, W. R. (2003) Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxyles-terase-2. Mol. Cancer Ther., 2: 765-771.
177. Ozaki, I., Yamamoto, K., Mizuta, T., Kajihara, S., Fukushima, N., Setoguchi, Y., Morito, F. and Sakai, T. (1998) Differential expression of laminin receptors in human hepatocellular carcinoma. Gut, 43: 837-842.
178. Ozu, C., Kikuci, E, Menendez, S, Cardo, CC, Logg, CR, Kasahara, N, Bochner, B (2005). Tissue-specific gene therapy by replication-competent retroviral vector for prostate cancer with fludarabine phosphate. Paper presented at: American Society of Gene Therapy Annual Meeting (St Louis, USA).
179. Packer, R.J., Raffel, C., Villablanca, J.G., Tonn, J.C., Burdach, S.E., Burger, K., LaFond, D., McComb, J.G., Cogen, P.H., Vezina, G. and Kapcala, L.P. (2000) Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J. Neurosurg., 92: 249-254.
180. Paielli, D.L., Wing, M.S., Rogulski, K.R., Gilbert, J.D., Kolozsvary, A., Kim, J.H., Hughes, J., Schnell, M., Thompson, T. and Freytag, S.O. (2000) Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol. Ther., 1: 263-274.
181. Palmer, D.H., Mautner, V., Mirza, D., Oliff, S., Gerritsen, W., van der Sijp, J.R., Hubscher, S., Reynolds, G., Bonney, S., Rajaratnam, R., Hull, D., Horne, M., Ellis, J., Mountain, A., Hill, S., Harris, P. A., Searle, P. F., Young, L. S., James, N. D. and Kerr, D. J. (2004) Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J. Clin. Oncol., 22: 1546-1552.
182. Pavlovic, J., Nawrath, M., Tu, R., Heinicke, T. and Moelling, K. (1996) Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V). Gene Ther., 3: 635-643.
183. Pawlik, T.M., Nakamura, H., Mullen, J.T., Kasuya, H., Yoon, S.S., Chandrasekhar, S., Chiocca, E.A. and Tanabe, K.K. (2002) Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer, 95: 1171-1181.
184. Pecora, A.L., Rizvi, N., Cohen, G.I., Meropol, N.J., Sterman, D., Marshall, J.L., Goldberg, S., Gross, P., O'Neil, J.D., Groene, W.S., Roberts, M. S., Rabin, H., Bamat, M. K. and Lorence, R. M. (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol., 20: 2251-2266.
185. Pellinen, R., Hakkarainen, T., Wahlfors, T., Tulimaki, K., Ketola, A., Tenhunen, A., Salonen, T. and Wahlfurs, J. (2004) Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy. Int. J. Oncol, 25: 1753-1762.
186. Peng, K.W., Donovan, K.A., Schneider, U., Cattaneo, R., Lust, J.A. and Russell, S.J. (2003) Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood, 101: 2557-2562.
187. Peng, K.W., Facteau, S., Wegman, T., O'Kane, D. and Russell, S.J. (2002) Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med., 8: 527-531.
188. Peplinski, G.R., Tsung, K., Casey, M.J., Meko, J.B., Fredrickson, T.N., Buller, R. M. and Norton, J.A. (1996) In Vivo Murine Tumor Gene Delivery and Expression by Systemic Recombinant Vaccinia Virus Encoding Interleukin- 1beta. Cancer J. Sci. Am, 2: 21.
189. Porosnicu, M., Mian, A. and Barber, G.N. (2003) The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res., 63: 8366-8376.
190. Porter, C. (2004) Retroviral vectors for suicide gene therapy. Methods Mol. Med, 90: 91-106.
191. Post, D.E., Fulci, G., Chiocca, E.A. and Van Meir, E.G. (2004) Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr. Gene Ther., 4: 41-51.
192. Post, D.E., Khuri, F.R., Simons, J.W. and Van Meir, E.G. (2003) Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum. Gene Ther., 14: 933-946.
193. Prados, M.D., McDermott, M., Chang, S.M., Wilson, C.B., Fick, J., Culver, K.W., Van Gilder, J., Keles, G.E., Spence, A. and Berger, M. (2003) Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial. J. Neurooncol., 65: 269-278.
194. Puhlmann, M., Gnant, M., Brown, C.K., Alexander, H.R. and Bartlett, D.L. (1999) Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum. Gene Ther., 10: 649-657.
195. Pyles, R.B., Warnick, R.E., Chalk, C.L., Szanti, B.E. and Parysek, L.M. (1997) A novel multiply-mutated HSV- 1 strain for the treatment of human brain tumors. Hum. Gene Ther., 8: 533-544.
196. Rainov, N.G. (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther., 11: 2389-2401.
197. Rainov, N.G., Kramm, C.M., Aboody-Guterman, K., Chase, M., Ueki, K., Louis, D.N., Harsh, G.R.t., Chiocca, A. and Breakefield, X.O. (1996) Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther., 3: 99-106.
198. Rainov, N.G. and Ren, H. (2003) Clinical trials with retrovirus mediated gene therapy - what have we learned? J. Neurooncol, 65: 227-236.
199. Ram, Z., Culver, K.W., Walbridge, S., Blaese, R.M. and Oldfield, E.H. (1993a) In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res., 53: 83-88.
200. Ram, Z., Culver, K.W., Walbridge, S., Frank, J.A., Blaese, R.M. and Oldfield, E.H. (1993b) Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J. Neurosurg., 79: 400-407.
201. Rampling, R., Cruickshank, G., Papanastassiou, V., Nicoll, J., Hadley, D., Brennan, D., Petty, R., MacLean, A., Harland, J., McKie, E., Mabbs, R. and Brown, M. (2000) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther., 7: 859-866.
202. Raper, S.E., Chirmule, N., Lee, F.S., Wivel, N.A., Bagg, A., Gao, G.P., Wilson, J.M. and Batshaw, M.L. (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab., 80: 148-158.
203. Rauen, K.A., Sudilovsky, D., Le, J.L., Chew, K.L., Hann, B., Weinberg, V., Schmitt, L.D. and McCormick, F. (2002) Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res., 62: 3812-3818.
204. Reid, T., Galanis, E., Abbruzzese, J., Sze, D. andrews, J., Romel, L., Hatfield, M., Rubin, J. and Kirn, D. (2001) Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther., 8: 1618-1626.
205. Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Wein, L.M. andrews, J., Randlev, B., Heise, C., Uprichard, M., Hatfield, M., Rome, L., Rubin, J. and Kirn, D. (2002) Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res., 62: 6070-6079.
206. Ren, W., Strube, R., Zhang, X., Chen, S.Y. and Huang, X.F. (2004) Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res., 64: 6645-6651.
207. Rogulski, K.R., Wing, M.S., Paielli, D.L., Gilbert, J.D., Kim, J.H. and Freytag, S.O. (2000) Double suicide gene therapy augments the antitumor activity of a replication-competent lyric adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther., 11: 67-76.
208. Russell, S.J. (2002) RNA viruses as virotherapy agents. Cancer Gene Ther., 9: 961-966.
209. Ryan, P.C., Jakubczak, J.L., Stewart, D.A., Hawkins, L.K., Cheng, C., Clarke, L.M., Ganesh, S., Hay, C., Huang, Y., Kaloss, M., Marinov, A., Phipps, S. S., Reddy, P. S., Shirley, P. S., Skripchenko, Y., Xu, L., Yang, J., Forry-Schaudies, S. and Hallenbeck, P. L. (2004) Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther., 11: 555-569.
210. Sakai, S., Kawabata, K., Tanaka, S., Harimoto, N., Hashimoto, I., Mu, C., Salmons, B., Ijima, H. and Kawakami, K. (2005) Subsieve-size agarose capsules enclosing ifosfamide-activating cells: a strategy toward chemotherapeutic targeting to tumors. Mol. Cancer Ther., 4: 1786-1790.
211. Salmons, B., Lohr, M. and Gunzburg, W.H. (2003) Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial. J. Gastroenterol., 38 Suppl 15: 78-84.
212. Samel, S., Keese, M., Lux, A., Jesnowski, R., Prosst, R., Saller, R., Hafner, M., Sturm, J., Post, S. and Lohr, M. (2006) Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide. Cancer Gene Ther., 13: 65-73.
213. Sandmair, A.M., Turunen, M., Tyynela, K., Loimas, S., Vainio, P., Vanninen, R., Vapalahti, M., Bjerkvig, R., Janne, J. and Yla-Herttuala, S. (2000) Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions. Cancer Gene Ther., 7: 413-421.
214. Schepelmann, S., Hallenbeck, P., Ogilvie, L.M., Hedley, D., Friedlos, F., Martin, J., Scanlon, I., Hay, C., Hawkins, L.K., Marais, R. and Springer, C.J. (2005) Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res., 65: 5003-5008.
215. Schmidt, M., Katano, H., Bossis, I. and Chiorini, J.A. (2004) Cloning and characterization of a bovine adeno-associated virus. J. Virol., 78: 6509-6516.
216. Schoensiegel, F., Paschen, A., Sieger, S., Eskerski, H., Mier, W., Rothfels, H., Kleinschmidt, J., Schadendorf, D. and Haberkom, U. (2004) MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma. Cancer Gene Ther., 11: 408-418.
217. Shand, N., Weber, F., Mariani, L., Bernstein, M., Gianella-Borradori, A., Long, Z., Sorensen, A.G. and Barbier, N. (1999) A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther., 10: 2325-2335.
218. Sharma, S.K., Pedley, R.B., Bhatia, J., Boxer, G.M., El-Emir, E., Qureshi, U., Tolner, B., Lowe, H., Michael, N.P., Minton, N., Begent, R. H. and Chester, K. A. (2005) Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin. Cancer Res., 11: 814-825.
219. Shen, Y. and Nemunaitis, J. (2005) Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol. Ther., 11: 180-195.
220. Shen, Y. and Nemunaitis, J. (2006) Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther., 13: 975-92.
221. Shi, W. and Bartlett, J.S. (2003) RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther., 7: 515-525.
222. Siders, W.M., Halloran, P.J. and Fenton, R.G. (1998) Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus. Cancer Gene Ther., 5: 281-291.
223. Simpson, G.R., Han, Z., Liu, B., Wang, Y., Campbell, G. and Coffin, R.S. (2006) Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res., 66: 4835-4842.
224. Solly, S.K., Trajcevski, S., Frisen, C., Holzer, G.W., Nelson, E., Clerc, B., Abordo-Adesida, E., Castro, M., Lowenstein, P. and Klatzmann, D. (2003) Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther., 10: 30-39.
225. Spooner, R.A., Martin, J., Friedlos, F., Marais, R. and Springer, C.J. (2000) In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug. Cancer Gene Ther., 7: 1348-1356.
226. Springer, C.J. (2004a) Introduction to vectors for suicide gene therapy. Methods Mol. Med, 90: 29-46.
227. Springer, C.J. and Niculescu-Duvaz, I. (2000) Prodrug-activating systems in suicide gene therapy. J. Clin. Invest., 105: 1161-1167.
228. Springer, C.J.e. (2004b). Suicide gene therapy: Methods and reviews. (New Jersey, Humana Press Inc.).
229. Steinwaerder, D.S., Carlson, C.A., Otto, D.L., Li, Z.Y., Ni, S. and Lieber, A. (2001) Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector. Nat. Med., 7: 240-243.
230. Sterman, D.H., Recio, A., Vachani, A., Sun, J., Cheung, L., DeLong, P., Amin, K.M., Litzky, L.A., Wilson, J.M., Kaiser, L.R. and Albelda, S.M. (2005) Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin. Cancer Res., 11: 7444-7453.
231. Stubdal, H., Perin, N., Lemmon, M., Holman, P., Bauzon, M., Potter, P.M., Danks, M.K., Fattaey, A., Dubensky, T. and Johnson, L. (2003) A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer Res., 63: 6900-6908.
232. Su, H., Lu, R., Chang, J.C. and Kan, Y.W. (1997) Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice. Proc. Natl. Acad. Sci. USA, 94: 13891-13896.
233. Su, H., Lu, R., Ding, R. and Kan, Y.W. (2000) Adeno-associated viral-mediated gene transfer to hepatoma: thymidine kinase/interleukin 2 is more effective in tumor killing in non-ganciclovir (GCV)-treated than in GCV-treated animals. Mol. Ther., 1: 509-515.
234. Sung, M.W., Yeh, H.C., Thung, S.N., Schwartz, M.E., Mandeli, J.P., Chen, S.H. and Woo, S.L. (2001) Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol. Ther., 4: 182-191.
235. Tai, C.K., Wang, W.J., Chen, T.C. and Kasahara, N. (2005) Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol. Ther., 12: 842-851.
236. Takamiya, Y., Short, M.P., Ezzeddine, Z.D., Moolten, F.L., Breakefield, X.O. and Martuza, R.L. (1992) Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosci. Res., 33: 493-503.
237. Tamiya, T., Wei, M.X., Chase, M., Ono, Y., Lee, F., Breakefield, X.O. and Chiocca, E.A. (1995) Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells. Gene Ther., 2: 531-538.
238. Themis, M., Waddington, S.N., Schmidt, M., von Kalle, C., Wang, Y., Al-Allaf, F., Gregory, L.G., Nivsarkar, M., Holder, M.V., Buckley, S.M., Dighe, N., Ruthe, A. T., Mistry, A., Bigger, B., Rahim, A., Nguyen, T. H., Trono, D., Thrasher, A. J. and Coutelle, C. (2005) Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol. Ther., 12: 763-771.
239. Toda, M., Martuza, R.L. and Rabkin, S.D. (2001) Combination suicide/ cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther., 8: 332-339.
240. Tollefson, A.E., Ryerse, J.S., Scaria, A., Hermiston, T.W. and Wold, W.S. (1996a) The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology, 220: 152-162.
241. Tollefson, A.E., Scaria, A., Hermiston, T.W., Ryerse, J.S., Wold, L.J. and Wold, W.S. (1996b) The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol., 70: 2296-2306.
242. Toth, K., Tarakanova, V., Doronin, K., Ward, P., Kuppuswamy, M., Locke, J.E., Dawson, J.E., Kim, H.J. and Wold, W.S. (2003) Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther., 10: 193-200.
243. Tseng, J.C., Levin, B., Hirano, T., Yee, H., Pampeno, C. and Meruelo, D. (2002) In vivo antitumor activity of Sindbis viral vectors. J. Natl. Cancer Inst., 94: 1790-1802.
244. Tseng, J.C., Levin, B., Hurtado, A., Yee, H., Perez de Castro, I., Jimenez, M., Shamamian, P., Jin, R., Novick, R.P., Pellicer, A. and Meruelo, D. (2004) Systemic tumor targeting and killing by Sindbis viral vectors. Nat. Biotechnol., 22: 70-77.
245. Tseng, J.C., Zanzonico, P.B., Levin, B., Finn, R., Larson, S.M. and Meruelo, D. (2006) Tumor-Specific In Vivo Transfection with HSV-1 Thymidine Kinase Gene Using a Sindbis Viral Vector as a Basis for Prodrug Ganciclovir Activation and PET. J. Nucl. Med., 47: 1136-1143.
246. Tsuchiyama, T., Kaneko, S., Nakamoto, Y., Sakai, Y., Honda, M., Mukaida, N. and Kobayashi, K. (2003) Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma. Cancer Gene Ther., 10: 260-269.
247. Tyminski, E., Leroy, S., Terada, K., Finkelstein, D.M., Hyatt, J.L., Danks, M.K., Potter, P.M., Saeki, Y. and Chiocca, E.A. (2005) Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res., 65: 6850-6857.
248. van der Eb, M.M., de Leeuw, B., van der Eb, A.J. and Hoeben, R.C. (2004) Side effects of suicide gene therapy. Methods. Mol. Med., 90: 479-490.
249. VandenDriessche, T., Cullen, D. and Chuah, M.K. (2003) Biosafety of onco-retroviral vectors. Curr. Gene Ther., 3:501-515.
250. Varghese, S. and Rabkin, S.D. (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther., 9: 967-978.
251. Wagner, J.A., Nepomuceno, I.B., Messner, A.H., Moran, M.L., Batson, E.P., Dimiceli, S., Brown, B.W., Desch, J.K., Norbash, A.M., Conrad, C.K., Guggino, W. B., Flotte, T. R., Wine, J. J., Carter, B. J., Reynolds, T. Moss, R. B. and Gardner P. (2002) A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum. Gene Ther., 13: 1349-1359.
252. Wang, W.J., Tai, C.K., Kasahara, N. and Chen, T.C. (2003) Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum. Gene Ther., 14: 117-127.
253. Wang, Y., Xue, S.A., Hallden, G., Francis, J., Yuan, M., Griffin, B.E. and Lemoine, N.R. (2005a) Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors. Cancer Res., 65: 1523-1531.
254. Wang, Z., Cai, L. and Wang, H. (2005b) Gene therapy of adenovirus mediated CD ::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer. Gynecol. Oncol., 96: 643-650.
255. Whitman, E.D., Tsung, K., Paxson, J. and Norton, J.A. (1994) In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery, 116: 183-188.
256. Wildner, O., Blaese, R.M. and Morris, J.C. (1999) Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res., 59: 410-413.
257. Wildner, O. and Morris, J.C. (2000) The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res., 60: 4167-4174.
258. Wolkersdorfer, G.W., Morris, J.C., Ehninger, G. and Ramsey, W.J. (2004) Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma. J. Gene Med., 6: 652-662.
259. Wu, Z., Asokan, A. and Samulski, R.J. (2006) Adeno-associated Virus Serotypes: Vector Toolkit for human gene therapy. Mol. Ther., 14: 316-27.
260. Xiong, W., Goverdhana, S., Sciascia, S.A., Candolfi, M., Zirger, J. M., Barcia, C., Curtin, J.F., King, G. D., Jaita, G., Liu, C., Kroeger, K., Agadjanian, H., Medina-Kauwe, L., Palmer, D., Ng, P., Lowenstein, P.R. and Castro, M.G. (2006) Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J. Virol., 80: 27-37.
261. Yamamoto, S., Suzuki, S., Hoshino, A., Akimoto, M. and Shimada, T. (1997) Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice. Cancer Gene Ther., 4: 91-96.
262. Yu, D.C., Chen, Y., Dilley, J., Li, Y., Embry, M., Zhang, H., Nguyen, N., Amin, P., Oh, J. and Henderson, D.R. (2001) Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res., 61: 517-525.
263. Zeh, H.J. and Bartlett, D.L. (2002) Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther., 9: 1001-1012.
264. Zhan, J., Gao, Y., Wang, W., Shen, A., Aspelund, A., Young, M., Laquerre, S., Post, L. and Shen, Y. (2005) Tumor-specific intravenous gene delivery using oncolytic adenoviruses. Cancer Gene Ther., 12: 19-25.
265. Zhang, M., Li, S., Nyati, M.K., DeRemer, S., Parsels, J., Rehemtulla, A., Ensminger, W.D. and Lawrence, T.S. (2003) Regional delivery and selective expression of a high-activity yeast cytosine deaminase in an intrahepatic colon cancer model. Cancer Res., 63: 658-663.
266. Zhao, H. and Peeters, B.P. (2003) Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication. J. Gen. Virol., 84: 781-788.
267. Zrachia, A., Dobroslav, M., Blass, M., Kazimirsky, G., Kronfeld, I., Blumberg, P.M., Kobiler, D., Lustig, S. and Brodie, C. (2002) Infection of glioma cells with Sindbis virus induces selective activation and tyrosine phosphorylation of protein kinase C delta. Implications for Sindbis virus-induced apoptosis. J. Biol. Chem., 277: 23693-23701.
268. Zufferey, R., Nagy, D., Mandel, R.J., Naldini, L. and Trono, D. (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol., 15: 871-875.